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I.  INTRODUCTION 
We are human because of the interplay of many biological, 
historical, cultural determinants, which preserve the feeling of 
our fundamental unity and nourish the richness of our diversity.  
The international community, States and governments, 
scientists, actors of civil society and individuals are called upon 
to consider the human genome as one of the premises of 
freedom itself and not simply as raw material to manipulate at 
leisure.  At the same time, considering that scientific 
advancements in this field are likely to offer unprecedented 
tools against diseases, it is crucial to acknowledge that these 
opportunities should never become the privilege of few.  What 
is heritage of humanity entails sharing both of responsibilities 
and benefits.1  
In April 2015, Chinese officials announced that, for the first time, a team 
of Chinese scientists had successfully spliced, edited, and modified the genes 
of a non-viable human embryo at the germinal level.  Through the 
experiment ultimately failed, the study’s conduction confirmed worldwide 
rumors that germline testing on human test subjects is indeed underway.2  
Since the beginning of the twenty-first century, scientists have continuously 
discovered new technologies and processes in genomic engineering and gene 
modification, two segments of the biotechnology field.  But despite the 
immense potential for positive benefits to society, these technologies have 
led to increasing ethical, political, and legal concerns due to the lack of 
international and domestic guidelines, especially with regard to the 
modification of human genes.3  In 2012, a new technology known as 
CRISPR (clustered regularly interspaced short palindromic repeats), or 
                                                                                                                   
 1 U.N. Educ., Sci. & Cultural Org., Int’l Bioethics Comm., Report of the IBC on Updating 
Its Reflection on the Human Genome and Human Rights, ¶ 128 (Oct. 2, 2015), http://unesdoc. 
unesco.org/images/0023/002332/233258E.pdf [hereinafter IBC].   
 2 Lauren F. Friedman, These are the countries where it’s ‘legal’ to edit human embryos 
(hint: the US is one), BUS. INSIDER (Apr. 23, 2015, 2:15 PM), http://www.businessinsider. 
com/china-edited-human-genome-laws-2015-4.  Though the ethics of the process are still up 
in the air in the eyes of the world, the inventor of the technology stressed that the Chinese 
scientists broke no laws in their experimentation, id. 
 3 David Baltimore et al., A Prudent Path Forward for Genomic Engineering and Germline 
Gene Modification: A framework for open discourse on the use of CRISPR-Cas9 technology 
to manipulate the human genome is urgently needed, 348 SCIENCE 36, 36 (2015) (noting 
“genome modification technology offers unparalled potential for modifying human and 
nonhuman genomes”). 
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CRISPR-CAS-9, was discovered.4  This new modification process will allow 
for easier and more efficient gene modification than previous technologies, 
which tend to be time consuming, expensive, and sometimes dangerous.5  
Scientists and medical professionals believe this technology has the potential 
to cure and prevent a variety of genetic diseases and mutations in both non-
human and human genes.  However, the process requires changing DNA in 
the germinal stage of embryotic development in humans, meaning the new 
traits will be passed to the child at birth and become a permanent genetic trait 
in the future bloodline.6  The lack of consistent regulations within the 
international community continues to prevent scientists from developing 
proper boundaries for the use of this technology.  Consequently, each 
country has developed its own regulations, which in turn has created great 
diversity in the legal spectrum.7  At the same time, nearly all nations, 
including the United States, are members of international treaties and 
covenants establishing basic human rights with respect to the human 
genome.  One such treaty is the Universal Declaration on the Human 
Genome and Human Rights (Declaration).8  Any signatory country to these 
treaties is required to develop their domestic regulations dealing with 
genomic testing to meet the principles embedded within said treaties, and 
any future international regulations will be required to uphold these same 
principles in order to conform to international policy, though these treaties 
do not have the direct force of law.  
Technologies such as CRISPR are extremely controversial because of 
their ability to manipulate genes at a different level than previous gene 
modification techniques.9  The process involves modification of the germinal 
cells of the subject’s parents’ egg and sperm cells, the germinal stage of 
                                                                                                                   
 4 Andrew Pollack, Jennifer Doudna, a Pioneer Who Helped Simplify Genome Editing, 
N.Y. TIMES, May 11, 2015, https://www.nytimes.com/2015/05/12/science/Jennifer-doudna-cri 
spr-cas9-genetic-engineering.html. 
 5 Id. 
 6 Baltimore et al., supra note 3, at 36.  
 7 Friedman, supra note 2.  
 8 General Conference of UNESCO, Universal Declaration on the Human Genome and 
Human Rights, U.N. Doc. AIRES/53/152 (Dec. 9, 1998) [hereinafter Declaration].  The 
Declaration was unanimously passed by all seventy-seven national delegates in attendance.  
The Declaration was followed in 2005 by a complementing UNESCO Declaration titled the 
Universal Declaration on Bioethics and Human Rights which was signed by representatives of 
191 countries that further established the ideals embedded within the 1997 Declaration.  For 
an example of another such treaty, see General Conference of UNESCO, Universal 
Declaration on Bioethics and Human Rights (Oct. 19, 2005), http://portal.unesco.org/shs/en/fi 
le_download.php/46133e1f4691e4c6e57566763d474a4dBioethic_EN.pdf.  
 9 Antonio Regalado, Engineering the Perfect Baby: Scientists are developing ways to edit the 
DNA of tomorrow’s children. Should they stop before it’s too late?, MIT TECH. REV. (Mar. 5, 
2015), http://www.technologyreview.com/featuredstory/535661/engineering-the-perfect-baby/. 
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development, or in other words, the period immediately preceding 
fertilization and implantation, where the ovum undergoes the first stages of 
cell division.10  This means that changes could eventually extend beyond the 
therapeutic level to be used for enhancement, ultimately giving parents the 
ability to select, modify, and create exact genetic traits—a made-to-order 
“designer baby.”11  This creates not only ethical but also legal concerns and 
raises several pivotal questions.  Should this technology be extended to 
human gene modification or only be allowed on non-human genes?  If we 
allow the technology’s use in human gene modification, how far should the 
use be extended?  At what point does the use of the technology begin to 
violate the principles imbedded within certain international treaties?12   
This Note will first look at the general background of biotechnology and 
genetic modification techniques to explain the differences between 
therapeutic and enhancement modification.  Next, it will examine current 
regulations and laws in several countries to illustrate the varying degrees of 
restrictiveness of current regulations.  The Note will then analyze the 
Declaration to determine what problems might arise in the creation of 
international regulations involving human genome modification, specifically 
focusing on the issue of therapeutic versus enhancement uses and the 
potential for “designer babies.”  Finally, this Note will evaluate how far this 
technology could extend while still falling within the accepted international 
values embedded in the Declaration.  This Note will not attempt to evaluate 
the legitimacy of current countries’ individual regulations or to debate the 
ethical aspects of the human genome modification issue.  
                                                                                                                   
 10 Kendra Cherry, The Germinal Stage (Apr. 26, 2016), http://psychology.about.com/od/gi 
ndex/g/germinal-stage.htm. 
 11 Obinna Morton & Phil Bolton, Biotech Summit Launches Atlanta to the Front in 
Developing Ethical Norms, GLOB. ATLANTA (Aug. 4, 2015), http://www.globalatlanta.com/artic 
le/27755/biotech-summit-launches-atlanta-to-the-front-in-developing-ethical-norms/ (suggesting 
that while “designer babies” are not the focus of the new technology, they are still a possibility).  
 12 For examples of international treaties involving the human genome, see General 
Conference of UNESCO, supra note 8.  
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II.  BACKGROUND OF THE BIOTECHNOLOGY FIELD AND ITS USE OF GENETIC 
MODIFICATION 
A.  Biotechnology and the Implementation of Germline Modification in 
Society  
The word biotechnology was coined by Karl Ereky in Hungary in 1919,13 
but informal applications of the technology date back thousands of years to 
the nomadic societies selective crop cultivation techniques.14  
“Biotechnology” is a cross between the Greek words bios meaning 
“everything to do with life” and technikos meaning “involving human 
knowledge and skills.”15  Biotechnology involves the application of scientific 
and engineering principles to the processing of materials by biological 
agents.”16  More simply, it is using living organisms to make useful 
products,17 but to describe it in more practical terms, biotechnology 
“harnesses cellular and biomolecular processes to develop technologies and 
products that help improve our lives and the health of our planet.”18  
Biotechnology is credited with providing products that can be used to 
“combat debilitating and rare diseases, reduce our environmental footprint, 
feed the hungry, use less and cleaner energy, and have safer, cleaner, and 
more efficient industrial manufacturing processes.”19  Biotechnology often 
uses genetic engineering, a method of creating new life forms and organic 
material by gene-splicing and other techniques,20 as one of its main 
processes.  An example of one such process is germline gene modification.  
In a germline gene transfer, the germinal cells of the subject’s parents’ egg 
and sperm cells are targeted prior to implantation and genetically modified 
with the goal of passing on the changes to the offspring, who will then carry 
the gene as a portion of its genetic makeup upon birth.21  This modification 
can be achieved through a variety of methods, but perhaps the most 
noteworthy is the newly discovered CRISPR technology that can be used to 
                                                                                                                   
 13 Ashish Swarup Verma et al., Biotechnology in the Realm of History, 3 J. PHARM. 
BIOALLIED SCI. 321, 321 (2001). 
 14 Id. at 322. 
 15 Europabio, What is Biotechnology?, http://www.europabio.org/what-biotechnology (last 
visited Oct. 28, 2016). 
 16 Id. 
 17 Id. 
 18 Biotechnology Indus. Org., What is Biotechnology?, https://www.bio.org/articles/what-bi 
otechnology (last visited Oct. 4, 2015). 
 19 This is not an exhaustive list.  For more uses of biotechnology, see id.  
 20 Genetic Engineering, BLACK’S LAW DICTIONARY (9th ed. 2009).  
 21 National Human Genome Research Institute, Germline Gene Transfer, GENOME.GOV 
(Mar. 2006), http://www.genome.gov/10004764.  
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modify DNA in the nuclei of reproductive cells.  The change is achieved by 
going in while the cells are still dividing to remove a portion of the DNA 
sequence and replace it with another, different, pre-selected, and pre-created 
sequence.22  Unlike previous techniques, CRISPR allows scientists to carry 
out modification in fertilized embryos both in vivo and in vitro, guaranteeing 
a permanent alteration in the genetic makeup that will be passed on to the 
parents’ progeny and to future generations.23  
B.  Creating the “Designer Baby” 
Despite CRISPR’s very recent creation, germline modification 
technologies are not a wholly new concept amongst the scientific community 
or even the general population.  The fear of a genetically modified society 
has been depicted in both the literary world and pop culture dating back 
nearly 100 years now and was perhaps most famously portrayed in Aldous 
Huxley’s 1932 novel, Brave New World:24 
A squat grey building of only thirty-four stories.  Over the main 
entrance the words, CENTRAL LONDON HATCHERY AND 
CONDITIONING CENTRE, and, in a shield, the World State’s 
motto, COMMUNITY, IDENTITY, STABILITY . . . Wintriness 
responded to wintriness.  The overalls of the workers were 
white, their hands gloved with a pale corpse-coloured rubber.  
The light was frozen, dead, a ghost.  Only from the yellow 
barrels of the microscopes did it borrow a certain rich and living 
substance, lying along the polished tubes like butter, streak after 
luscious streak in long recession down the work tables.  “And 
this,” said the Director opening the door, “is the Fertilizing 
Room.”25 
                                                                                                                   
 22 Id.  
 23 Baltimore et al., supra note 3, at 37.  See generally Motoko Araki & Tetsuya Ishii, 
International regulatory landscape and integration of corrective genome editing into in vitro 
fertilization, REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY (Nov. 24, 2014), http://www.rbej. 
com/content/12/1/108 (explaining the scientific process of specific germline modification 
techniques).  
 24 RONALD M. GREEN, BABIES BY DESIGN: THE ETHICS OF GENETIC CHOICE 107–09 (1997) 
(briefly summarizing the plot of Brave New World and explaining its connection to today’s 
society).  
 25 This quotation illustrates a society that has replaced the vitality of human conception 
with “cold, mechanical processes,” taking the humanity out of procreation.  Id. at 107 (quoting 
Aldous Huxley, Brave New World 1 (1932)).  
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Huxley’s fear proved to be prophetic, because in the United Kingdom in 
1978, a woman named Louise Brown became the first successful “test-tube 
baby,” and the possibilities for scientifically enhanced procreation began.26  
A world that had previously relied on chance, prayer, and luck to achieve 
successful procreation now had new hope through the possibility of in vitro 
fertilization.  In 1997, the same year Dolly the sheep was successfully 
cloned, the film Gattaca was released, and it provided yet another glimpse 
into the effects of genetic modification.27  In one of the most famous scenes 
from the film, when the parents of the main character, Vincent, go to “order” 
a brother for him, the geneticist tells them: 
You want to give your child the best possible start.  Believe 
me, we have enough imperfection built-in already.  Your child 
doesn’t need any additional burdens.  And keep in mind, this 
child is still you, simply the best of you.  You could conceive 
naturally a thousand times and never get such a result.28 
In this single statement, the movie illustrates the potential problem with the 
development of successful germline modification techniques: though these 
techniques have the potential to cure deadly illnesses, it becomes nearly 
impossible for society to determine the appropriate boundaries when giving 
parents the ability to “play God.”  Human germline modification can be 
separated into two distinct processes, germline treatment, also known as 
germline transfer, and germline enhancement.29  Germline treatment or 
transfer is considered negative genetic engineering and aims to prevent or 
treat disease.30  On the other side of the spectrum is germline enhancement or 
positive genetic engineering, which aims to enhance a particular capability or 
trait.31  Most people tend to accept that technological advances are 
                                                                                                                   
 26 Ferris Jabr, Are We Too Close to Making Gattaca a Reality?, SCI. AM. (Oct. 28, 2013), 
http://blogs.scientificamerican.com/brainwaves/are-we-too-close-to-making-gattaca-a-reality/. 
 27 Id. The film Gattaca tells the story of Vincent Freeman, one of the last of the genetically 
unmodified naturally conceived children in a new genetically enhanced world, where life 
expectancy and disease likelihood are ascertained at birth.  Myopic and due to die at thirty, he 
has no chance of a career in a society that now discriminates on the basis of genes, rather than 
gender, race, or religion.  Gattaca (Sony Pictures 1997), PHILOSOPHICAL FILMS, http://www.ph 
ilfilms.utm.edu/1/gattaca.htm (last visited Oct. 5, 2015). 
 28 Jabr, supra note 26. 
 29 See GREEN, supra note 24, at 53–70 for a more complete explanation of the categories of 
genetic modification.  
 30 Fritz Allhoff, Germ-line Genetic Enhancement and Rawlsian Primary Goods, 18 J. 
EVOLUTION & TECH. 10 (2008), http://jetpress.org/v18/allhoff.htm.  
 31 Id.  
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appropriate in the first category, the treatment side.32  The process of 
selecting traits to create and order these “designer babies” falls within the 
second category, where most of the controversy is found.33  The question 
then becomes, “does a couple’s procreative liberty protect their freedom to 
select or shape offspring characteristics . . . . as part of discretion in rearing 
offspring,”34 and are there any legal protections behind this choice?  The 
debate has been highly contested, especially considering the current state of 
guidelines on the matter and the complete lack of direction in this area.35 
C.  The Biotech Boom in the State of Georgia  
While debates continue in the international field as to the proper protocol 
for these new technologies, the implementation of formal regulations could 
greatly impact the state of Georgia as it “seeks to raise its profile as a center 
for bioscience research and development.”36  From 2010 to 2015, 2,400 new 
bioscience jobs were created in the state.37  Since 2010, Georgia has 
blossomed in the biotechnology field due to new discoveries and ideas that 
have emerged from the state’s research universities, particularly the Georgia 
Institute of Technology and Emory University, as well as a large number of 
startup companies interested in expanding the field.38  The city of Atlanta, 
with aspirations of being a future hub of biotechnology, provides a 
“business-friendly” climate that currently puts few roadblocks in the paths of 
those who want to start a new venture in the field or to relocate existing 
ventures to the state.  The Atlanta metro area currently supplies ready access 
to large groups of patients for a number of firms already doing clinical trials 
on drugs or medical devices.39  The creation of accepted international 
                                                                                                                   
 32 GREEN, supra note 24. 
 33 Id.  
 34 JOHN A. ROBERTSON, CHILDREN OF CHOICE: FREEDOM AND THE NEW REPRODUCTIVE 
TECHNOLOGIES 165 (1994) (discussing the various slippery slope arguments made against 
allowing nontherapeutic gene interventions).  
 35 See Jabr, supra note 26; cf. Robertson, supra note 34, at 24 (arguing that while 
nontherapeutic enhancement is not covered by the doctrine of procreative liberty, it could fall 
within the discretion that is traditionally granted to parents in making decisions about how to 
rear their offspring).  
 36 Morton & Bolton, supra note 11.  
 37 Id. 
 38 See Randy Southerland, Biotech Boom, GA. TREND (Oct. 2014), http://www.georgiatrend. 
com/October-2014/Biotech-Boom/, for a general background in the developments from these 
higher education institutes.  
 39 Atlanta, Georgia is the home of a variety of biotechnology companies and healthcare IT 
providers ranging from start-up companies—like Axion Biosystems, which was started by a 
student at Georgia Tech—to world-renowned giants like Baxter International and McKesson. 
The state’s biotech industry now employs more than 120,000 people and has a $30 billion 
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regulations with clearer guidelines on human testing has the potential to 
create many new jobs dedicated to research.  Furthermore, the regulations 
have the potential to allow for more money to be funneled into research, 
which would benefit Georgia’s higher learning institutions.  This in turn 
would allow for safer, more efficient techniques to be developed and 
streamlined into Georgia’s biotechnology businesses.  However, legal status 
of such technologies as a result of any future regulations will determine the 
ultimate potential for growth in the field.  A broad legal framework could 
initiate the above-mentioned expansions, while a narrow framework would 
severely limit the availability of these new jobs and the amount of money 
allocated for future research.  
III.  PROVIDING A LEGAL FRAMEWORK FOR ANALYSIS IN THE REGULATORY 
AND INTERNATIONAL SCHEME  
With a lack of consistency in developing and implementing these 
technologies, a problem arises in determining which country’s domestic 
regulations or laws meet, or will meet, the international standards, bearing in 
mind that international standards are nearly nonexistent at present.  The lack 
of guidance in the international field has forced scientists to attempt to 
reconcile the level of different legal schemes with international covenants 
and treaties and decide what, if any, processes may be in violation of such 
schemes.  In order to understand the issue, it becomes important to examine 
the regulations and current state of the law.  
Unfortunately, U.S. law on germline modification technologies is 
relatively non-existent, and what does exist is questionable as to whether 
CRISPR technology specifically fits underneath its umbrella.  Presently in 
the United States, there is huge diversity in state regulations,40 and it is not 
clear whether any federal law or federal regulations directly address the 
genetic modification, particularly germline enhancements, of embryos.41  
Most likely the uncertainty is because until recently the technology was only 
                                                                                                                   
annual economic impact.  It is surpassed in this regard by only a few other U.S. biotech hubs 
like Boston and San Diego. Id. The city of Atlanta is also home to the American Cancer 
Society and the Center for Disease Control.  Jerry Grillo, Georgia’s Biotech Future: The 
industry accounts for 62,000 jobs, $3.6 billion in labor income and $517 million in tax 
revenues . . . but we’re not there yet, GA. TREND (May 2010), http://www.georgiatrend.com/ 
May-2010/Georgias-Biotech-Future/.  
 40 President’s Council on Bioethics (U.S.), Reproduction and Responsibility: The Regulation 
of New Biotechnologies (2004), https://bioethicsarchive.georgetown.edu/pcbe/reports/reproducti 
onandresponsibility/chapter4.html.  
 41 Id. 
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speculative.42  However, gene-transfer research falls clearly under federal 
regulation by the Food and Drug Administration of the United States 
(FDA).43  The FDA has been granted authority over gene therapy by both the 
Federal Food, Drug, and Cosmetic Act and the Public Health Safety Act—
which requires gene therapies to be subject to clinical trials for 
Investigational New Drugs (INDs).44  However, there are no ethical 
requirements within these statutes.45  It is clear that the FDA is required to 
oversee articles intended to “diagnose, cure, mitigate, treat, or prevent 
disease,” but enhancements do not fit within these categories.46  Though no 
consensus has been reached on the matter, the FDA has argued that its 
authority extends over all products related to diseases or conditions in human 
beings, and because enhancements involve conditions of human beings, it 
must have the authority to regulate enhancements.47  This argument has been 
unpersuasive to date.  Thus, germline modification appears to be 
unregulated.48 
The FDA is further supplemented by the United States National Institutes 
of Health (NIH) that supplies a forum for the consideration of social and 
ethical issues dealing with germline modifications.49  But because the NIH is 
not a regulatory agency, their authority is limited to determining what 
technological processes deserve funding.50  The NIH Recombinant DNA 
Advisory Committee stated explicitly in a portion of the NIH Guidelines for 
Research Involving Recombinant or Synthetic Nucleic Acid Molecules of 
2013 that the United States “will not at present entertain proposals for 
germline alterations,” but it is not statutorily disallowed at this point in 
time.51  
                                                                                                                   
 42 Girard Kelly, Choosing the Genetics of Our Children: Options for Framing Public 
Policy, 30 SANTA CLARA HIGH TECH. L.J. 303, 336 (2013).  See also Emily Marden & 
Dorothy Nelkin, Displaced Agendas: Current Regulatory Strategies for Germline Gene 
Therapy, 45 MCGILL L.J. 461, 473 (2000). 
 43 Kelly, supra note 42, at 336.  
 44 Committee on the Independent Review and Assessment of the Activities of the NIH 
Recombinant DNA Advisory Committee; Oversight and Review of Clinical Gene Transfer 
Protocols: Assessing the Role of the Recombinant DNA Advisory Committee (2014), https:// 
www.ncbi.nlm.nih.gov/books/NBK195894/. 
 45 Marden & Nelkin, supra note 42, at 474–75.  
 46 Id.   
 47 Oversight and Review of Clinical Gene Transfer Protocols, supra note 44. 
 48 “Enhancements” in this sense refers to both the therapeutic and enhancement function of 
germline technologies. Id.  
 49 Id. 
 50 Id. at 477.  
 51 Edward Lanphier et al., Don’t edit the human germ line, NATURE (Mar. 12, 2015), http:// 
www.nature.com/news/don-t-edit-the-human-germ-line-1.17111.  To view the complete text 
of the NIH 2013 Guidelines, see National Institutes of Health, NIH Guidelines for Research 
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Like the United States, many other countries have somewhat ambiguous 
regulations.52  In the Act on Artificial Fertilisation and Use of Human 
Gametes and Embryos for Stem-Cell Research of Iceland, research, 
experiments, and procedures on in vitro fertilization embryos to enhance the 
understanding of the causes of congenital diseases and miscarriages may be 
permitted.  However, the Act’s position on germline gene modification for 
reproduction is not explicitly stated.53   Similarly, China has the Guidelines 
on Human Assisted Reproductive Technologies of 2003, which specifies that 
using human egg plasma and nuclear transfer technology for the purpose of 
reproduction and manipulation of the genes in human gametes, zygotes, or 
embryos for the purpose of reproduction is prohibited.  However, these 
guidelines do not have the force of law, leaving ambiguity in whether or not 
the practice is actually banned, especially with their recent ventures in 
2015.54 
Alternatively, while several countries appear to have ambiguities in their 
accepted practices, many countries have taken strict positions in banning the 
use of germline modification for enhancement purposes.  Canada, and most 
European countries, completely ban the technology.55   In 2004, Canada 
passed the Assisted Human Reproduction Act that states, “altering the 
genome of a cell of a human being or in vitro embryo such that the alteration 
is capable of being transmitted to descendants is prohibited.”56   
The international field is not currently clear on the subject either.  
However, in April 2015 an international summit was held in Atlanta, 
Georgia, to discuss and begin drafting potential international regulations for 
germline modification.57  The summit was called Biotech and the Ethical 
Imagination, a Global Summit (BEINGS).58  BEINGS was brought about 
                                                                                                                   
Involving Recombinant or Synthetic Nucleic Acid Molecules (Apr. 2016), http://osp.od.nih. 
gov/sites/default/files/NIH_Guidelines.html.  
 52 Friedman, supra note 2; see also Araki & Ishii, supra note 23. 
 53 See Araki & Ishii, supra note 23, at tbl.S1.  
 54 Id. 
 55 Friedman, supra note 2.  
 56 Araki & Ishii, supra note 23, at tbl.S1.   
 57 Around one hundred and forty delegates including some of the world’s top faculty and 
researchers in the field attended the BEINGS Summit. Fourteen universities in the state 
participated, which brought support from organizations including the Coca-Cola Co., the 
Marcus Foundation, the Metro Atlanta Chamber, the Georgia Research Alliance, Georgia Bio 
and Southeast Bio.  BEINGS 2015 also partnered with Central Atlanta Progress, the Atlanta 
Downtown Improvement District, the Atlanta Convention and Visitors Bureau and received 
support from the Consulate General of France and John Parkerson, the honorary consul 
general of Hungary.  Morton & Bolton, supra note 11.  
 58 See generally BEINGS, http://www.beings2015.org (last visited Oct. 5, 2015) 
(containing more information about the BEINGS Summit held in Atlanta, Ga). 
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because “there is a kind of regulatory chaos in the world community around 
biotechnology . . . . [with] some countries hav[ing] very conservative policies 
and others very liberal.”  BEINGS was followed up when, in December of 
2015, a group of scientists, policy experts, and bio-ethicists met in 
Washington, D.C. for the International Summit of Human Gene Editing, to 
discuss the implications of human gene editing and how these technologies 
would be regulated moving forward.59  They decided not to universally ban 
editing on the human genome but left the decision up to each country to 
individually determine the extent the use of such technologies would be 
allowed per their respective law.  However, many scientists and researchers 
urged for a moratorium until these technologies can be evaluated further.60  
Despite these two meetings, international regulations are still a thing of the 
future.61  Instead, countries and researchers must look to international treaties 
and covenants on human rights and the human genome to determine what are 
and are not accepted international practices. 
IV.  ANALYSIS 
With the lack of guidelines, scientists must look to the principles 
embedded in the abovementioned international treaties and their own 
countries’ domestic laws for guidance on the proper use of these new 
technologies.  “The Declaration sets universal ethical standards on human 
genetic research and practices which balance the freedom of scientists to 
pursue their work in the field with the need to safeguard human rights and 
protect humanity from potential abuses.”62  The Declaration’s main articles 
attempt to establish some limitations on what is appropriate with gene 
intervention when it concerns “the genetic heritage of humanity and in 
individuals.”63  As the Declaration explains, “the international community 
has a moral obligation not to transgress.”64  There are three basic principles 
                                                                                                                   
 59 Sara Reardon, Global summit reveals divergent views on human gene editing, NATURE 
(Dec. 8, 2015), http://www.nature.com/news/global-summit-reveals-divergent-views-on-hum 
an-gene-editing-1.18971. 
 60 Id. 
 61 See BEINGS, supra note 58. 
 62 EurekAlert, UNESCO Adopts Universal Declaration On The Human Genome And 
Human Rights (Nov. 11, 1997), http://www.eurekalert.org/pub_releases/1997-11/U-UAUD-11 
1197.php (explaining what brought about the need for the Declaration and a more in depth 
discussion of its components).  
 63 Id.  
 64 This quotation refers to the inability to transgress the “heritage of humanity” discussed 
supra note 62.  Declaration, supra note 8.  See also Prue Taylor, The Common Heritage of 
Mankind: A Bold Concept Kept Within Strict Boundaries, WEALTH OF THE COMMONS, 
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that go to the heart of the Declaration.65  The first principle states that “the 
human genome is part of the heritage of humanity.”66  The heritage of 
humanity is an ethical concept that asserts that “some localities belong to all 
humankind” and all resources, both tangible and intangible, should be 
available for the use and benefit of the general public while taking into 
account needs of developing countries and future generations.67  The second 
principle specifies a requirement of “respect for the dignity and human rights 
of every individual regardless of his/her genetic characteristics.”68  The final 
principle is a “rejection of genetic determinism.”69  Genetic determinism is 
the theory that character and behavioral traits are determined singularly by 
the genes that make up a person’s genotype,70 by recognizing that the human 
genome, because it is subject to mutations through evolution, contains 
“potentialities that are expressed differently according to each individual’s 
natural and social environment.”71  The issue that remains is whether 
scientists will be able to square technologies like CRISPR with these three 
main principles of the Declaration.  
A.  Brief Discussion of the Components of the Declaration  
Several articles within the Declaration deserve careful interpretation and 
could create potential issues in the creation of international regulations.  The 
opening two articles are at the core of the debate, establishing that the human 
genome is a pivotal aspect of the living world as it “underlies the 
fundamental unity of all members of the human family,” and international 
regulations must respect the “inherent dignity and diversity” of all human 
beings.72  These articles establish that technology cannot overstep boundaries 
by interfering with the inherent right of human dignity.73  In other words, 
according to the Declaration, regardless of the genetic characteristics of a 
                                                                                                                   
http://wealthofthecommons.org/essay/common-heritage-mankind-bold-doctrine-kept-within-st 
rict-boundaries (last visited Jan. 9, 2016) (discussing “the heritage of mankind”).  
 65 EurekAlert, supra note 62.  
 66 Id.  
 67 For more information on the “heritage of mankind” see Taylor, supra note 64.  
 68 EurekAlert, supra note 62.  
 69 Id. 
 70 Genetic Determinism, REFERENCEMD (June 6, 2012), http://www.reference.md/files/D033/ 
mD033141.html.  But see David B. Resnik & Daniel B. Vorhaus, Genetic Modification and 
Genetic Determinism, PHILOSOPHIES, ETHICS, AND HUMANITIES IN MEDICINE 1:9 (June 26, 2006), 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1524970/pdf/1747-5341-1-9.pdf (suggesting that 
there may be more to traits than genes alone).  
 71 EurekAlert, supra note 62.  
 72 Declaration, supra note 8, art. 1. 
 73 Id. 
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person, there is nothing that can override his right to respect for his dignity 
and diversity, and no man-made law can diminish such rights.  To further 
exemplify this principle, Article Ten states that “[n]o research or research 
application concerning the human genome . . . should prevail over respect for 
the human rights, fundamental freedoms and human dignity of individuals 
or . . . groups of people.”74  Scholars, jurists, and philosophers have long 
argued over the definition of “human dignity.”75  The European Court of 
Human Rights has stated that dignity is “a particularly vague concept, and 
one subject to random interpretation,”76 therefore making it difficult to 
determine precisely what dignity means outside of a factual setting.  
However, the basis of dignity is said to lie in autonomy of self that is 
“reflected in every human being’s right to individual self-determination,”77 
thus establishing that such a universal right cannot be infringed upon by law 
because it adheres to individual personhood that is created merely by being a 
part of humanity.78  To state it more clearly, human dignity is a respect 
derived automatically from one’s status as a human being, that prevails over 
all other values,79 and because this basic ideal is so generally recognized, it 
appears that there is a general agreement as to what human dignity means at 
its core: the right to respect of one’s individual personhood and uniqueness.  
The Declaration specifies that practices that go against human dignity shall 
not be permitted.80  One explicitly stated practice against human dignity is 
human cloning, though no others are specifically mentioned.81  It is 
important to note that at the time the Declaration was drafted, scientists had 
                                                                                                                   
 74 Id. art. 10.  
 75 Rex D. Glensy, The Right to Dignity, 43 COLUM. HUM. RTS. L. REV. 65, 66 (2011).  
 76 In the case of Siliadin v. France, the European Court of Human Rights considered 
trafficking in human beings for the first time.  The applicant, a minor female Togolese 
national who lived in Paris, had served as an unpaid servant for several years.  Relying on 
Article Four of the European Convention (prohibition of slavery and forced labor), the child 
argued that French criminal law did not provide her sufficient protection against the 
“servitude” or the “forced and compulsory” labor, which in practice had made her a domestic 
slave.  The court considered that the applicant had, at the least, been subjected to forced labor 
and held in servitude within the meaning of Article Four of the Convention, which was against 
human dignity.  However, the Court held that it could not be considered that the applicant had 
been held in slavery in the traditional sense of that concept.  Siliadin v. France, 43 Eur. Ct. 
H.R. 16, 317 (2005).  
 77 Glensy, supra note 75, at 67. 
 78 Matthais Mahlmann, The Basic Law at 60—Human Dignity and the Culture of 
Republicanism, 11 GERMAN L.J. (SPECIAL ISSUE) 9 (2010).  
 79 Mette Lebech, What is Human Dignity? (2004), http://eprints.maynoothuniversity.ie/39 
2/1/Human_Dignity.pdf (giving a complete historical background of the origin of the phrase 
human dignity). 
 80 Id. 
 81 Declaration, supra note 8, art. 1.  
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heightened levels of sensitivity to cloning because of the successful 
completion of the cloning process in Dolly the sheep.  The threat to human 
dignity apparent during the initial forms of genetic modification was at the 
forefront in the reasoning for such a specific inclusion and has continued to 
be hotly contested.82  
A second category of requirements for genetic modification that has the 
potential to shape the direction of international regulations involves informed 
consent.  The Declaration specifies that free and informed consent must be 
obtained before any “research, treatment or diagnosis affecting an 
individual’s genome” can be performed.83  It continues in the same article to 
state that “[i]f according to the law a person does not have the capacity to 
consent, research affecting his or her genome may only be carried out for his 
or her direct health benefit, subject to the authorization and the protective 
conditions prescribed by law.”84  The Declaration clarifies that if research 
does not have an expected health benefit, it can only be continued through an 
exception to the general rule and must be done with the “utmost restraint.”  
Any such research is allowed only if it exposes the person to a “minimal risk 
and minimal burden.”85  The Declaration does specify that there is an 
exception to consent for those who are unable to consent, in this case 
embryos, that allows third parties to make that choice and consent for them if 
it is in their best interest, but this exception still requires that there be a 
medical benefit.86 
B.  Can CRISPR Be Squared with the Declaration? 
So exactly how far can these technologies extend without contravening 
international principles and ethics?  One form of biotechnology already 
mentioned, CRISPR, can be split into three major categories: non-human 
genome modification, human genome modification with regards to genetic 
diseases and their treatment, and human genome modification with regards to 
physical traits and enhancement.87  The Declaration makes clear that it is 
concerned with human genomes in particular, therefore the economic 
                                                                                                                   
 82 Noëlle Lenoire, Comment, Universal Declaration on the Human Genome and Human 
Rights: The First Legal and Ethical Framework at the Global Level, 30 COLUM. HUM. RTS. L. 
REV. 537, 555 (1999).  Representatives from Germany suggested an amendment be added to 
also preclude germline modification in this Article, but it was rejected by other state 
representatives. Id. at 555–56.  
 83 Declaration, supra note 8, art. 5(a)-(b). 
 84 Id. art. 5(e).  
 85 Id.  
 86 Id. 
 87 Baltimore et al., supra note 3. 
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benefits and relative lack of moral and social implications suggest non-
human modification practices will need little regulation and will always be 
allowed unless the specific technique is found to interfere with public 
health.88  
The second and third categories of modification, genetic treatment and 
genetic enhancement respectively,89 require more examination to reconcile 
them with the Declaration, but the analysis for both is ultimately the same.  
As noted above, the first major concern is that the technology must not 
violate the “human dignity.”90  Human dignity is a flexible term that is 
ultimately self-defining, creating an inherent problem due to the fact that 
every person will have a different definition of what his or her personal 
“human dignity” involves.  Scholars and jurists alike have accepted that the 
definition of the term “human dignity” changes through time with the 
development of new technology and changing social norms.91  Because the 
phrase is self-defining, the definition will ultimately change as people’s 
beliefs change, which tend to be further influenced by technological 
expansion.  Prior to the development of this technology, the possibility of 
germline modification was a mere fiction, a futuristic possibility that, while 
people tended to have opinions about, did not require them to actually decide 
whether the process was right or wrong under their belief system.  Now, with 
germline modification being at the forefront of the biotechnology field, 
people’s viewpoints on the matter are expanding and changing.92  As a result, 
people’s definitions of their personal human dignity must also change to 
allow them to adapt to the feasibility of such technology.  The result of 
constantly expanding viewpoints on the definition of human dignity suggests 
that such technology, regardless of whether it is therapeutic or enhancement 
based, can never be violative of human dignity because of the inherent 
flexibility of the term.93  However, at the same time, human dignity clearly 
                                                                                                                   
 88 Id.  
 89 See Alhoff, supra note 30, for a review of the differences on treatment versus 
enhancement modification. 
 90 Declaration, supra note 8.  
 91 See generally Glensy, supra note 75; Lebech, supra note 79.  
 92 Mairi Levitt, Would you edit your unborn child’s genes so they were successful?, CENTER 
FOR GENETICS AND SOCIETY (Nov. 3, 2015), http://www.geneticsandsociety.org/article.php?id 
=8966 (suggesting that parents must choose between seeking the best life for their child based 
on the genetic possibilities at the time, while keeping in mind that we live in a rapidly 
changing world and the success of genetic technologies is never guaranteed, and letting their 
child develop naturally).  
 93 Glensy, supra note 75, at 98, quoting Bundesverfassungsgericht [BVerfGE] [Federal 
Constitutional Court] June 21, 1977, 45 BVerfGE 187 (Ger.), reprinted in DONALD KOMMERS, 
THE CONSTITUTIONAL JURISPRUDENCE OF THE FEDERAL REPUBLIC OF GERMANY 306, 307 (2d 
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embraces the idea that “the differences among human beings, regardless of 
the measure of their endowment, are exactly what the recognition of their 
equality presupposes and therefore protects.”94   This suggests that changes 
in the germline that have the potential to create a means of discrimination or 
eliminate differences would always be against human dignity.  
As discussed earlier, cloning is specifically mentioned as being against 
human dignity.95  Therefore, it stands to reason that processes that are 
procedurally similar should, by default, go against human dignity.  Because 
cloning involves an entirely different process than CRISPR, it does not fit 
entirely into either the treatment or enhancement category but instead 
includes portions of both.  This means that the above statement from the 
Declaration alone cannot declare either category as a whole as going against 
human dignity.  Like cloning, both the treatment and enhancement categories 
involve the artificial selection and implantation of traits that are passed on 
through birth,96 naturally creating a means of discrimination and eliminating 
differences because the traits are scientifically generated and are uniform 
regardless of the host.  However, despite the technological similarities and 
discriminatory function, it may be possible to distinguish these processes and 
make the latter conform to the principles within the Declaration.97  The 
argument is that there is an inherent economic and social benefit in the 
prevention of genetic ailments versus in an artificial creation of life,98 so 
while cloning is cited in the Declaration as against human dignity, the 
prevention of medical ailments is distinguishable because it involves more 
than just artificial creation due to its preventative function.  In other words, 
the treatment category merely replaces damaged or harmful traits rather than 
creating new traits.  This must be contrasted to trait modification that lacks a 
therapeutic or medical function and falls solely within an enhancement 
function.  Opponents of artificial modification of human traits characterize 
practices lacking therapeutic value, such as specific trait selection, as another 
form of artificial creation of life that places little to no economic value in the 
ability to hand select traits because it lacks any preventative value.99  
Furthermore, critics believe it is unlikely that a technology carrying a risk of 
                                                                                                                   
and even change the evaluation’ of claims made under the right to dignity because the 
‘understanding of the content, function, and effect’ of this right can, and does, deepen”). 
 94 IBC, supra note 1, ¶ 111.  
 95 Declaration, supra note 8, art. 11. 
 96 Araki & Ishii, supra note 23.  
 97 Zoë Corbyn, CRISPR: Is It a Good Idea to Upgrade Our DNA?, THE GUARDIAN (May 
10, 2015, 2:30 AM), http://www.theguardian.com/science/2015/may/10/crispr-genome-editin 
g-dna-upgrade-technology-genetic-disease.  
 98 Id.  
 99 Regalado, supra note 9.  
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creating new forms of discrimination and stigmatization for those who 
cannot afford such enhancement or who do not want to use such technologies 
could ever be said to uphold human dignity.100  For the international 
community, this most likely means that technologies such as CRISPR will be 
limited in their scope if they intend to follow the principles embedded in the 
Declaration.101  In other words, the technology can be used in germline 
modification up to the extent that it begins to interfere with the natural 
creation of life before it goes against human dignity.  This means that uses 
having some preventative function would not be seen as an unnatural 
creation of life, whereas specific trait selection would.  Perhaps a better 
distinction is illustrated by thinking about the modification of traits being 
acceptable and the mere changing or switching of traits being unacceptable.  
The authors of the Declaration recognized that the ideals embedded in the 
document were not absolute and would require reexamination over time.102  
Article 24 of the Declaration specifies that the International Bioethics 
Community of UNESCO is required to further examine the issues raised by 
the application of such technology and the potential for evolution.103  It is 
further required to give advice “concerning the follow-up of th[e] 
Declaration, in particular regarding the identification of practices that could 
be contrary to human dignity, such as germ-line interventions.”104  
Opponents to germline modification argue that this clause of the Declaration 
views any form of technology that promotes modification at the germinal 
level as inherently against human dignity.105  Based on the specific mention 
of germline technology in the Declaration, it is apparent that the authors 
contemplated the effects such a technological feat would have on human 
dignity, but proponents for allowing the technology argue that their use of 
the word “could” instead of “would” combined with the necessity to further 
examine the issues derived from the application of such a technology signify 
an intent to delve deeper into the technology before determining that the 
technology as a whole automatically defies human dignity.106   
                                                                                                                   
 100 Id.  
 101 Nathaniel Comfort, Better Babies, AEON (Nov. 17, 2015), https://aeon.com/essays/the-
dream-of-designing-humans-has-a-long-and-peculiar-history. 
 102 Declaration, supra note 8, art. 24.  
 103 Id.  
 104 Id.  
 105 See, e.g., Stop Genetic Modification of Human Embryos and the Creation of 3-Parent 
Children, CITIZEN GO (Feb. 18, 2015), http://www.citizengo.org/en/17728-please-keep-uk-allo 
wing-germline-genetic-modification-human-embryos-and-creation-3-parent. 
 106 ANDERS NORDGREN, RESPONSIBLE GENETICS: THE MORAL RESPONSIBILITY OF GENETICISTS 
FOR THE CONSEQUENCES OF HUMAN GENETICS RESEARCH 183 (2001). 
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The International Bioethics Committee (IBC) recently issued a 
memorandum that helps to clarify their viewpoint on the issue. In the memo, 
which addressed the ethical challenges and practical implications of 
advancements in human genetics and biotechnology, the IBC created a 
distinction between germline technologies for the medical purposes of 
prevention, diagnostics, or therapy, from those with the goal of enhancing 
human genes; the first being acceptable and the latter as going against human 
dignity by creating unnecessary similarities in the recipients of the 
technology.107  This viewpoint supports the theory that the authors of the 
Declaration recognized that changes in technology would impact the 
definition of human dignity, and new technologies would need to be 
continually evaluated over time.  Upon their most recent examination the 
IBC seemed to emphasize the importance of regulations drawing a line for 
the acceptable use of the technology by placing restrictions on uses for non-
medical benefits.  The alternative would “jeopardize the inherent and 
therefore equal dignity of all human beings and renew eugenics, disguised as 
the fulfillment of the wish for a better, improved life.”108 
Even if the technology is established as being compatible with human 
dignity there are further requirements.  As discussed earlier, the Declaration 
also lists strict guidelines for when informed consent can be waived when 
dealing with processes affecting the human genome.109  It is apparent that an 
embryo is unable to give informed consent; therefore, the research, 
treatment, or diagnosis of the human genome must fall under one of the 
exceptions.  While proponents argue that the parents are the ones who are 
required to give informed consent and not the embryo, making this exception 
unnecessary,110 perhaps there is another way to reconcile the two differing 
viewpoints.  Genetic modification curing genetic abnormalities and diseases 
appears to fall under the “direct health benefit” that requires no consent.  
However, it is not clear whether mere modification of traits would ever have 
a health benefit and would therefore require an exception in order to be 
performed.111  Since the Declaration specifies that exceptions must be taken 
with the “utmost restraint,” it seems unlikely that international regulations 
                                                                                                                   
 107 IBC, supra note 1, ¶ 107.  
 108 Id.  
 109 Declaration, supra note 8, art. 5.   
 110 John A. Robertson, Procreative Liberty in the Era of Genomics, 29 AM. J.L. & MED. 439, 
477–78 (2004) (discussing whether parent’s procreative liberties are enough to allow them to 
edit their child’s genome before birth).  
 111 Tina Hesman Saey, Editing Human Germline Cells Sparks Ethics Debate, SCIENCENEWS 
(May 6, 2015, 4:17 PM), https://www.sciencenews.org/article/editing-human-germline-cells-
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would allow full-scale trait modification.112  Furthermore, the second part of 
the consent test is that it must have minimal risk and minimal burden to be 
undertaken.113  Based on the current scientific data of CRISPR use, there are 
inherent medical risks with the technology that must be thoroughly evaluated 
to make sure the risks do not outweigh the benefits.114  Because the process 
requires precision cuts of very specific gene sequences, the risk of 
accidentally splicing the gene in incorrect places is extremely high and could 
cause unintended mutations.  Oftentimes, even if the gene is spliced in the 
correct location, the newly inserted sequence may still bind to different 
locations upon insertion.115  This indicates that until CRISPR is thoroughly 
investigated and developed, it can never meet the standard of an allowable 
exception under the Declaration because there is too much of a health risk to 
the subject.  This is not an absolute ban, however.  The IBC addressed this 
issue in its recent memo, stating that the international community of 
scientific researchers must be thorough and constantly update the 
consequences of these technologies.116  This suggests that the Declaration did 
not mean to completely eliminate the use of all such technologies, despite 
risks.  The IBC does caution the international community on the implications 
of “medical tourism,” the concept that because of the lack of international 
guidelines once an application of a technology is legal in one country it is 
legal everywhere.117  Therefore, the “race to the first should be avoided.”118  
Taking the inherent medical risks and informed consent arguments into 
consideration, it seems highly unlikely that presently the international 
community can justify non-medical uses of CRISPR technology due to its 
complete lack of necessity, further supporting a line-drawing in its 
implementation of regulations.  
V.  CONCLUSION 
Ultimately, it seems that while some uses of CRISPR can be justified and 
reconciled with the Declaration, international regulations must be careful to 
distinguish between the “correction” of human genes and the “swapping” of 
                                                                                                                   
 112 Declaration, supra note 8, art. 5(2).  
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 116 IBC, supra note 1, ¶ 110. 
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them.  It is clear from the current legal scheme that the level of acceptance of 
any practice involving the human genome varies amongst countries; 
therefore, international regulations can be established on a clean slate.  
International regulations will probably allow technology to advance as far as 
medical benefits and correcting abnormalities in the genome are concerned 
but draw a line with respect to changing traits just to change traits, because it 
is seen as too much of an unnatural creation of life.  This means that 
regulations should distinguish between processes involving therapeutic 
values and those involving enhancement values.  The creation of new forms 
of discrimination and the elimination of differences through specific gene 
selection is likely to be found to go against human dignity—which values 
individual personhood above all else—and therefore this practice may be an 
invalid use of the technology.  Furthermore, it seems unlikely at this time 
that scientists have a valid argument for voiding consent, regardless of 
whether parents should be allowed to make this choice for their progeny 
even when it comes to enhancements, because they fail to have a direct 
health benefit.  It seems more likely that the prevention of diseases could be 
seen as directly beneficial to one’s health and may be an acceptable practice.  
At present, it seems that scientists should be strongly discouraged, even in 
those countries with lax regulations where it might be permitted.  The 
inherent health risks currently seem to outweigh the benefits, and it appears 
unlikely that waiving informed consent is a valid option.  This will enable 
pathways to responsible uses of this technology to be identified and will 
allow time for the ethical issues to be examined in light of the international 
ideals embedded within the cultures of the world and portrayed in 
international covenants, ultimately leading to international regulations to 
guide the scientific community in this ever changing field of genetic 
modification.  
